nodes	percent_of_prediction	percent_of_DWPC	metapath
Docetaxel—prostate cancer—urinary bladder cancer	0.379	1	CtDrD
Docetaxel—EGFR—urinary bladder cancer	0.169	1	CbGaD
Docetaxel—ABCC10—Gemcitabine—urinary bladder cancer	0.0334	0.128	CbGbCtD
Docetaxel—ABCC10—Etoposide—urinary bladder cancer	0.0239	0.0915	CbGbCtD
Docetaxel—ABCC10—Doxorubicin—urinary bladder cancer	0.0163	0.0624	CbGbCtD
Docetaxel—ABCC10—Methotrexate—urinary bladder cancer	0.0158	0.0605	CbGbCtD
Docetaxel—SLC22A7—Fluorouracil—urinary bladder cancer	0.0141	0.0539	CbGbCtD
Docetaxel—ABCC1—Epirubicin—urinary bladder cancer	0.0118	0.0454	CbGbCtD
Docetaxel—ABCB1—Mitomycin—urinary bladder cancer	0.0108	0.0415	CbGbCtD
Docetaxel—ABCC1—Etoposide—urinary bladder cancer	0.00922	0.0353	CbGbCtD
Docetaxel—CYP1B1—Doxorubicin—urinary bladder cancer	0.00885	0.0339	CbGbCtD
Docetaxel—SLCO1B3—Methotrexate—urinary bladder cancer	0.00881	0.0338	CbGbCtD
Docetaxel—ABCC2—Carboplatin—urinary bladder cancer	0.00813	0.0312	CbGbCtD
Docetaxel—SLC22A7—Methotrexate—urinary bladder cancer	0.00776	0.0297	CbGbCtD
Docetaxel—ABCG2—Fluorouracil—urinary bladder cancer	0.00739	0.0283	CbGbCtD
Docetaxel—ABCG2—Carboplatin—urinary bladder cancer	0.00735	0.0282	CbGbCtD
Docetaxel—ABCC2—Cisplatin—urinary bladder cancer	0.00694	0.0266	CbGbCtD
Docetaxel—ABCC2—Etoposide—urinary bladder cancer	0.00682	0.0262	CbGbCtD
Docetaxel—ABCC1—Doxorubicin—urinary bladder cancer	0.00629	0.0241	CbGbCtD
Docetaxel—ABCG2—Cisplatin—urinary bladder cancer	0.00628	0.0241	CbGbCtD
Docetaxel—ABCG2—Etoposide—urinary bladder cancer	0.00617	0.0236	CbGbCtD
Docetaxel—ABCC1—Methotrexate—urinary bladder cancer	0.00609	0.0233	CbGbCtD
Docetaxel—CYP3A4—Thiotepa—urinary bladder cancer	0.00492	0.0188	CbGbCtD
Docetaxel—ABCC2—Doxorubicin—urinary bladder cancer	0.00465	0.0178	CbGbCtD
Docetaxel—ABCC2—Methotrexate—urinary bladder cancer	0.00451	0.0173	CbGbCtD
Docetaxel—ABCG2—Doxorubicin—urinary bladder cancer	0.00421	0.0161	CbGbCtD
Docetaxel—ABCG2—Methotrexate—urinary bladder cancer	0.00408	0.0156	CbGbCtD
Docetaxel—CYP3A5—Etoposide—urinary bladder cancer	0.00342	0.0131	CbGbCtD
Docetaxel—ABCB1—Gemcitabine—urinary bladder cancer	0.00312	0.0119	CbGbCtD
Docetaxel—ABCB1—Cisplatin—urinary bladder cancer	0.00226	0.00868	CbGbCtD
Docetaxel—ABCB1—Etoposide—urinary bladder cancer	0.00222	0.00853	CbGbCtD
Docetaxel—ABCB1—Doxorubicin—urinary bladder cancer	0.00152	0.00582	CbGbCtD
Docetaxel—ABCB1—Methotrexate—urinary bladder cancer	0.00147	0.00563	CbGbCtD
Docetaxel—CYP3A4—Etoposide—urinary bladder cancer	0.00133	0.00511	CbGbCtD
Docetaxel—MAPT—prostate gland—urinary bladder cancer	0.00118	0.032	CbGeAlD
Docetaxel—KIF11—female reproductive system—urinary bladder cancer	0.0011	0.0298	CbGeAlD
Docetaxel—KIF11—vagina—urinary bladder cancer	0.000991	0.027	CbGeAlD
Docetaxel—MAP4—prostate gland—urinary bladder cancer	0.000925	0.0252	CbGeAlD
Docetaxel—CYP3A4—Doxorubicin—urinary bladder cancer	0.000909	0.00348	CbGbCtD
Docetaxel—BCL2—prostate gland—urinary bladder cancer	0.000841	0.0229	CbGeAlD
Docetaxel—EGFR—prostate gland—urinary bladder cancer	0.000831	0.0226	CbGeAlD
Docetaxel—MAP2—prostate gland—urinary bladder cancer	0.000728	0.0198	CbGeAlD
Docetaxel—KIF11—lymph node—urinary bladder cancer	0.000641	0.0174	CbGeAlD
Docetaxel—KIF11—Teniposide—Etoposide—urinary bladder cancer	0.000638	0.412	CbGdCrCtD
Docetaxel—MAP4—renal system—urinary bladder cancer	0.000631	0.0172	CbGeAlD
Docetaxel—BCL2—epithelium—urinary bladder cancer	0.000618	0.0168	CbGeAlD
Docetaxel—MAP2—seminal vesicle—urinary bladder cancer	0.000616	0.0168	CbGeAlD
Docetaxel—BCL2—smooth muscle tissue—urinary bladder cancer	0.000595	0.0162	CbGeAlD
Docetaxel—BCL2—renal system—urinary bladder cancer	0.000573	0.0156	CbGeAlD
Docetaxel—TUBB4A—prostate gland—urinary bladder cancer	0.000563	0.0153	CbGeAlD
Docetaxel—TUBB2B—prostate gland—urinary bladder cancer	0.000544	0.0148	CbGeAlD
Docetaxel—TUBB—prostate gland—urinary bladder cancer	0.000515	0.014	CbGeAlD
Docetaxel—TUBB2A—prostate gland—urinary bladder cancer	0.000512	0.0139	CbGeAlD
Docetaxel—TUBB6—prostate gland—urinary bladder cancer	0.000505	0.0137	CbGeAlD
Docetaxel—MAP4—female reproductive system—urinary bladder cancer	0.000505	0.0137	CbGeAlD
Docetaxel—CYP3A4—urine—urinary bladder cancer	0.000503	0.0137	CbGeAlD
Docetaxel—MAP2—urethra—urinary bladder cancer	0.000488	0.0133	CbGeAlD
Docetaxel—TUBB2B—seminal vesicle—urinary bladder cancer	0.00046	0.0125	CbGeAlD
Docetaxel—BCL2—female reproductive system—urinary bladder cancer	0.000459	0.0125	CbGeAlD
Docetaxel—MAP4—vagina—urinary bladder cancer	0.000457	0.0124	CbGeAlD
Docetaxel—ABCC10—prostate gland—urinary bladder cancer	0.000442	0.012	CbGeAlD
Docetaxel—TUBB4B—prostate gland—urinary bladder cancer	0.000439	0.0119	CbGeAlD
Docetaxel—TUBB—seminal vesicle—urinary bladder cancer	0.000435	0.0118	CbGeAlD
Docetaxel—TUBB2A—seminal vesicle—urinary bladder cancer	0.000433	0.0118	CbGeAlD
Docetaxel—SLC22A7—renal system—urinary bladder cancer	0.000429	0.0117	CbGeAlD
Docetaxel—TUBB6—seminal vesicle—urinary bladder cancer	0.000427	0.0116	CbGeAlD
Docetaxel—SLCO1B3—vagina—urinary bladder cancer	0.0004	0.0109	CbGeAlD
Docetaxel—MAP2—female reproductive system—urinary bladder cancer	0.000398	0.0108	CbGeAlD
Docetaxel—TUBB4A—renal system—urinary bladder cancer	0.000384	0.0104	CbGeAlD
Docetaxel—MAPT—lymph node—urinary bladder cancer	0.000376	0.0102	CbGeAlD
Docetaxel—ABCC10—seminal vesicle—urinary bladder cancer	0.000374	0.0102	CbGeAlD
Docetaxel—TUBB4B—seminal vesicle—urinary bladder cancer	0.000371	0.0101	CbGeAlD
Docetaxel—TUBB6—epithelium—urinary bladder cancer	0.000371	0.0101	CbGeAlD
Docetaxel—TUBB2B—renal system—urinary bladder cancer	0.000371	0.0101	CbGeAlD
Docetaxel—TUBB—smooth muscle tissue—urinary bladder cancer	0.000365	0.00992	CbGeAlD
Docetaxel—TUBB2B—urethra—urinary bladder cancer	0.000364	0.00991	CbGeAlD
Docetaxel—TUBB2A—smooth muscle tissue—urinary bladder cancer	0.000363	0.00987	CbGeAlD
Docetaxel—MAP2—vagina—urinary bladder cancer	0.00036	0.00979	CbGeAlD
Docetaxel—KIF11—Cytarabine—Gemcitabine—urinary bladder cancer	0.000359	0.232	CbGdCrCtD
Docetaxel—TUBB6—smooth muscle tissue—urinary bladder cancer	0.000358	0.00973	CbGeAlD
Docetaxel—ABCC2—prostate gland—urinary bladder cancer	0.000355	0.00966	CbGeAlD
Docetaxel—CYP1B1—prostate gland—urinary bladder cancer	0.000348	0.00946	CbGeAlD
Docetaxel—TUBB—urethra—urinary bladder cancer	0.000345	0.00938	CbGeAlD
Docetaxel—TUBB6—renal system—urinary bladder cancer	0.000344	0.00937	CbGeAlD
Docetaxel—TUBB2A—urethra—urinary bladder cancer	0.000343	0.00933	CbGeAlD
Docetaxel—TUBB6—urethra—urinary bladder cancer	0.000338	0.0092	CbGeAlD
Docetaxel—TUBB6—Zalcitabine—Gemcitabine—urinary bladder cancer	0.000321	0.207	CbGdCrCtD
Docetaxel—ABCC1—prostate gland—urinary bladder cancer	0.000313	0.00851	CbGeAlD
Docetaxel—TUBB4B—smooth muscle tissue—urinary bladder cancer	0.000311	0.00846	CbGeAlD
Docetaxel—TUBB4A—female reproductive system—urinary bladder cancer	0.000307	0.00836	CbGeAlD
Docetaxel—ABCC10—renal system—urinary bladder cancer	0.000301	0.0082	CbGeAlD
Docetaxel—TUBB4B—renal system—urinary bladder cancer	0.000299	0.00814	CbGeAlD
Docetaxel—TUBB2B—female reproductive system—urinary bladder cancer	0.000297	0.00808	CbGeAlD
Docetaxel—ABCC10—urethra—urinary bladder cancer	0.000296	0.00806	CbGeAlD
Docetaxel—MAP4—lymph node—urinary bladder cancer	0.000295	0.00804	CbGeAlD
Docetaxel—TUBB4B—urethra—urinary bladder cancer	0.000294	0.008	CbGeAlD
Docetaxel—TUBB2A—female reproductive system—urinary bladder cancer	0.00028	0.00761	CbGeAlD
Docetaxel—TUBB6—female reproductive system—urinary bladder cancer	0.000276	0.0075	CbGeAlD
Docetaxel—TUBB2B—vagina—urinary bladder cancer	0.000269	0.00731	CbGeAlD
Docetaxel—BCL2—lymph node—urinary bladder cancer	0.000269	0.00731	CbGeAlD
Docetaxel—EGFR—lymph node—urinary bladder cancer	0.000265	0.00722	CbGeAlD
Docetaxel—ABCC1—seminal vesicle—urinary bladder cancer	0.000265	0.0072	CbGeAlD
Docetaxel—ABCG2—prostate gland—urinary bladder cancer	0.000259	0.00705	CbGeAlD
Docetaxel—TUBB—vagina—urinary bladder cancer	0.000254	0.00692	CbGeAlD
Docetaxel—TUBB2A—vagina—urinary bladder cancer	0.000253	0.00688	CbGeAlD
Docetaxel—TUBB6—vagina—urinary bladder cancer	0.000249	0.00679	CbGeAlD
Docetaxel—CYP1B1—smooth muscle tissue—urinary bladder cancer	0.000246	0.0067	CbGeAlD
Docetaxel—ABCC2—renal system—urinary bladder cancer	0.000242	0.00659	CbGeAlD
Docetaxel—ABCC10—female reproductive system—urinary bladder cancer	0.000241	0.00657	CbGeAlD
Docetaxel—CYP3A5—prostate gland—urinary bladder cancer	0.00024	0.00654	CbGeAlD
Docetaxel—TUBB4B—female reproductive system—urinary bladder cancer	0.00024	0.00652	CbGeAlD
Docetaxel—CYP1B1—renal system—urinary bladder cancer	0.000237	0.00645	CbGeAlD
Docetaxel—MAP2—lymph node—urinary bladder cancer	0.000233	0.00633	CbGeAlD
Docetaxel—ABCG2—seminal vesicle—urinary bladder cancer	0.000219	0.00596	CbGeAlD
Docetaxel—ABCC10—vagina—urinary bladder cancer	0.000218	0.00594	CbGeAlD
Docetaxel—TUBB4B—vagina—urinary bladder cancer	0.000217	0.0059	CbGeAlD
Docetaxel—ABCC1—urethra—urinary bladder cancer	0.000209	0.0057	CbGeAlD
Docetaxel—ABCC2—female reproductive system—urinary bladder cancer	0.000194	0.00527	CbGeAlD
Docetaxel—CYP1B1—female reproductive system—urinary bladder cancer	0.00019	0.00517	CbGeAlD
Docetaxel—TUBB4A—lymph node—urinary bladder cancer	0.00018	0.00489	CbGeAlD
Docetaxel—TUBB2B—lymph node—urinary bladder cancer	0.000174	0.00473	CbGeAlD
Docetaxel—ABCG2—urethra—urinary bladder cancer	0.000173	0.00472	CbGeAlD
Docetaxel—TUBB—lymph node—urinary bladder cancer	0.000164	0.00447	CbGeAlD
Docetaxel—CYP3A5—renal system—urinary bladder cancer	0.000164	0.00446	CbGeAlD
Docetaxel—TUBB2A—lymph node—urinary bladder cancer	0.000164	0.00445	CbGeAlD
Docetaxel—TUBB—Azacitidine—Gemcitabine—urinary bladder cancer	0.000163	0.105	CbGdCrCtD
Docetaxel—TUBB6—lymph node—urinary bladder cancer	0.000161	0.00439	CbGeAlD
Docetaxel—ABCC1—vagina—urinary bladder cancer	0.000154	0.0042	CbGeAlD
Docetaxel—ABCC10—lymph node—urinary bladder cancer	0.000141	0.00384	CbGeAlD
Docetaxel—TUBB4B—lymph node—urinary bladder cancer	0.00014	0.00382	CbGeAlD
Docetaxel—ABCG2—vagina—urinary bladder cancer	0.000128	0.00348	CbGeAlD
Docetaxel—ABCB1—prostate gland—urinary bladder cancer	0.000128	0.00347	CbGeAlD
Docetaxel—CYP3A4—renal system—urinary bladder cancer	0.000123	0.00335	CbGeAlD
Docetaxel—CYP3A5—vagina—urinary bladder cancer	0.000119	0.00323	CbGeAlD
Docetaxel—ABCC2—lymph node—urinary bladder cancer	0.000113	0.00309	CbGeAlD
Docetaxel—CYP1B1—lymph node—urinary bladder cancer	0.000111	0.00302	CbGeAlD
Docetaxel—ABCB1—seminal vesicle—urinary bladder cancer	0.000108	0.00294	CbGeAlD
Docetaxel—ABCC1—lymph node—urinary bladder cancer	9.99e-05	0.00272	CbGeAlD
Docetaxel—CYP3A4—female reproductive system—urinary bladder cancer	9.85e-05	0.00268	CbGeAlD
Docetaxel—ABCB1—epithelium—urinary bladder cancer	9.38e-05	0.00255	CbGeAlD
Docetaxel—ABCB1—renal system—urinary bladder cancer	8.7e-05	0.00237	CbGeAlD
Docetaxel—ABCB1—urethra—urinary bladder cancer	8.55e-05	0.00233	CbGeAlD
Docetaxel—ABCG2—lymph node—urinary bladder cancer	8.27e-05	0.00225	CbGeAlD
Docetaxel—ABCB1—female reproductive system—urinary bladder cancer	6.97e-05	0.0019	CbGeAlD
Docetaxel—TUBB6—Azacitidine—Gemcitabine—urinary bladder cancer	6.74e-05	0.0435	CbGdCrCtD
Docetaxel—ABCB1—vagina—urinary bladder cancer	6.3e-05	0.00172	CbGeAlD
Docetaxel—ABCB1—lymph node—urinary bladder cancer	4.08e-05	0.00111	CbGeAlD
Docetaxel—Pruritus—Fluorouracil—urinary bladder cancer	2.67e-05	0.000275	CcSEcCtD
Docetaxel—Infestation NOS—Doxorubicin—urinary bladder cancer	2.67e-05	0.000275	CcSEcCtD
Docetaxel—Infestation—Doxorubicin—urinary bladder cancer	2.67e-05	0.000275	CcSEcCtD
Docetaxel—Visual impairment—Methotrexate—urinary bladder cancer	2.66e-05	0.000275	CcSEcCtD
Docetaxel—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	2.64e-05	0.000272	CcSEcCtD
Docetaxel—Hypersensitivity—Cisplatin—urinary bladder cancer	2.64e-05	0.000272	CcSEcCtD
Docetaxel—Diarrhoea—Gemcitabine—urinary bladder cancer	2.63e-05	0.000271	CcSEcCtD
Docetaxel—Renal failure—Doxorubicin—urinary bladder cancer	2.62e-05	0.00027	CcSEcCtD
Docetaxel—Erythema multiforme—Methotrexate—urinary bladder cancer	2.61e-05	0.000269	CcSEcCtD
Docetaxel—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	2.61e-05	0.000269	CcSEcCtD
Docetaxel—Haemoglobin—Epirubicin—urinary bladder cancer	2.6e-05	0.000268	CcSEcCtD
Docetaxel—Jaundice—Doxorubicin—urinary bladder cancer	2.6e-05	0.000268	CcSEcCtD
Docetaxel—Stomatitis—Doxorubicin—urinary bladder cancer	2.6e-05	0.000268	CcSEcCtD
Docetaxel—Rhinitis—Epirubicin—urinary bladder cancer	2.59e-05	0.000267	CcSEcCtD
Docetaxel—Abdominal pain—Etoposide—urinary bladder cancer	2.59e-05	0.000267	CcSEcCtD
Docetaxel—Body temperature increased—Etoposide—urinary bladder cancer	2.59e-05	0.000267	CcSEcCtD
Docetaxel—Conjunctivitis—Doxorubicin—urinary bladder cancer	2.59e-05	0.000267	CcSEcCtD
Docetaxel—Haemorrhage—Epirubicin—urinary bladder cancer	2.59e-05	0.000267	CcSEcCtD
Docetaxel—Hepatitis—Epirubicin—urinary bladder cancer	2.59e-05	0.000267	CcSEcCtD
Docetaxel—Eye disorder—Methotrexate—urinary bladder cancer	2.58e-05	0.000266	CcSEcCtD
Docetaxel—Diarrhoea—Fluorouracil—urinary bladder cancer	2.58e-05	0.000266	CcSEcCtD
Docetaxel—Hypoaesthesia—Epirubicin—urinary bladder cancer	2.57e-05	0.000265	CcSEcCtD
Docetaxel—Asthenia—Cisplatin—urinary bladder cancer	2.57e-05	0.000265	CcSEcCtD
Docetaxel—Pharyngitis—Epirubicin—urinary bladder cancer	2.57e-05	0.000265	CcSEcCtD
Docetaxel—Cardiac disorder—Methotrexate—urinary bladder cancer	2.56e-05	0.000264	CcSEcCtD
Docetaxel—Urinary tract disorder—Epirubicin—urinary bladder cancer	2.55e-05	0.000263	CcSEcCtD
Docetaxel—Oedema peripheral—Epirubicin—urinary bladder cancer	2.55e-05	0.000263	CcSEcCtD
Docetaxel—Connective tissue disorder—Epirubicin—urinary bladder cancer	2.54e-05	0.000262	CcSEcCtD
Docetaxel—Urethral disorder—Epirubicin—urinary bladder cancer	2.53e-05	0.000261	CcSEcCtD
Docetaxel—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	2.52e-05	0.00026	CcSEcCtD
Docetaxel—Epistaxis—Doxorubicin—urinary bladder cancer	2.51e-05	0.000259	CcSEcCtD
Docetaxel—Angiopathy—Methotrexate—urinary bladder cancer	2.51e-05	0.000259	CcSEcCtD
Docetaxel—Immune system disorder—Methotrexate—urinary bladder cancer	2.5e-05	0.000257	CcSEcCtD
Docetaxel—Dizziness—Fluorouracil—urinary bladder cancer	2.5e-05	0.000257	CcSEcCtD
Docetaxel—Visual impairment—Epirubicin—urinary bladder cancer	2.49e-05	0.000257	CcSEcCtD
Docetaxel—Mediastinal disorder—Methotrexate—urinary bladder cancer	2.49e-05	0.000257	CcSEcCtD
Docetaxel—Agranulocytosis—Doxorubicin—urinary bladder cancer	2.49e-05	0.000256	CcSEcCtD
Docetaxel—Chills—Methotrexate—urinary bladder cancer	2.48e-05	0.000256	CcSEcCtD
Docetaxel—Diarrhoea—Cisplatin—urinary bladder cancer	2.45e-05	0.000252	CcSEcCtD
Docetaxel—Erythema multiforme—Epirubicin—urinary bladder cancer	2.45e-05	0.000252	CcSEcCtD
Docetaxel—Alopecia—Methotrexate—urinary bladder cancer	2.44e-05	0.000252	CcSEcCtD
Docetaxel—Vomiting—Gemcitabine—urinary bladder cancer	2.44e-05	0.000252	CcSEcCtD
Docetaxel—Mental disorder—Methotrexate—urinary bladder cancer	2.42e-05	0.00025	CcSEcCtD
Docetaxel—Rash—Gemcitabine—urinary bladder cancer	2.42e-05	0.00025	CcSEcCtD
Docetaxel—Dermatitis—Gemcitabine—urinary bladder cancer	2.42e-05	0.000249	CcSEcCtD
Docetaxel—Eye disorder—Epirubicin—urinary bladder cancer	2.42e-05	0.000249	CcSEcCtD
Docetaxel—Hypersensitivity—Etoposide—urinary bladder cancer	2.41e-05	0.000249	CcSEcCtD
Docetaxel—Malnutrition—Methotrexate—urinary bladder cancer	2.41e-05	0.000248	CcSEcCtD
Docetaxel—Erythema—Methotrexate—urinary bladder cancer	2.41e-05	0.000248	CcSEcCtD
Docetaxel—Haemoglobin—Doxorubicin—urinary bladder cancer	2.4e-05	0.000248	CcSEcCtD
Docetaxel—Headache—Gemcitabine—urinary bladder cancer	2.4e-05	0.000248	CcSEcCtD
Docetaxel—Flushing—Epirubicin—urinary bladder cancer	2.4e-05	0.000247	CcSEcCtD
Docetaxel—Cardiac disorder—Epirubicin—urinary bladder cancer	2.4e-05	0.000247	CcSEcCtD
Docetaxel—Vomiting—Fluorouracil—urinary bladder cancer	2.4e-05	0.000247	CcSEcCtD
Docetaxel—Rhinitis—Doxorubicin—urinary bladder cancer	2.4e-05	0.000247	CcSEcCtD
Docetaxel—Haemorrhage—Doxorubicin—urinary bladder cancer	2.39e-05	0.000247	CcSEcCtD
Docetaxel—Hepatitis—Doxorubicin—urinary bladder cancer	2.39e-05	0.000247	CcSEcCtD
Docetaxel—Hypoaesthesia—Doxorubicin—urinary bladder cancer	2.38e-05	0.000245	CcSEcCtD
Docetaxel—Rash—Fluorouracil—urinary bladder cancer	2.38e-05	0.000245	CcSEcCtD
Docetaxel—Dermatitis—Fluorouracil—urinary bladder cancer	2.38e-05	0.000245	CcSEcCtD
Docetaxel—Pharyngitis—Doxorubicin—urinary bladder cancer	2.37e-05	0.000245	CcSEcCtD
Docetaxel—Headache—Fluorouracil—urinary bladder cancer	2.36e-05	0.000244	CcSEcCtD
Docetaxel—Urinary tract disorder—Doxorubicin—urinary bladder cancer	2.36e-05	0.000244	CcSEcCtD
Docetaxel—Oedema peripheral—Doxorubicin—urinary bladder cancer	2.36e-05	0.000243	CcSEcCtD
Docetaxel—Dysgeusia—Methotrexate—urinary bladder cancer	2.36e-05	0.000243	CcSEcCtD
Docetaxel—Asthenia—Etoposide—urinary bladder cancer	2.35e-05	0.000242	CcSEcCtD
Docetaxel—Connective tissue disorder—Doxorubicin—urinary bladder cancer	2.35e-05	0.000242	CcSEcCtD
Docetaxel—Angiopathy—Epirubicin—urinary bladder cancer	2.35e-05	0.000242	CcSEcCtD
Docetaxel—Urethral disorder—Doxorubicin—urinary bladder cancer	2.35e-05	0.000242	CcSEcCtD
Docetaxel—Immune system disorder—Epirubicin—urinary bladder cancer	2.34e-05	0.000241	CcSEcCtD
Docetaxel—Mediastinal disorder—Epirubicin—urinary bladder cancer	2.33e-05	0.00024	CcSEcCtD
Docetaxel—Back pain—Methotrexate—urinary bladder cancer	2.33e-05	0.00024	CcSEcCtD
Docetaxel—Chills—Epirubicin—urinary bladder cancer	2.32e-05	0.000239	CcSEcCtD
Docetaxel—Pruritus—Etoposide—urinary bladder cancer	2.32e-05	0.000239	CcSEcCtD
Docetaxel—Arrhythmia—Epirubicin—urinary bladder cancer	2.31e-05	0.000238	CcSEcCtD
Docetaxel—Visual impairment—Doxorubicin—urinary bladder cancer	2.31e-05	0.000238	CcSEcCtD
Docetaxel—Alopecia—Epirubicin—urinary bladder cancer	2.29e-05	0.000236	CcSEcCtD
Docetaxel—Nausea—Gemcitabine—urinary bladder cancer	2.28e-05	0.000235	CcSEcCtD
Docetaxel—Vomiting—Cisplatin—urinary bladder cancer	2.27e-05	0.000235	CcSEcCtD
Docetaxel—Mental disorder—Epirubicin—urinary bladder cancer	2.27e-05	0.000234	CcSEcCtD
Docetaxel—Erythema multiforme—Doxorubicin—urinary bladder cancer	2.26e-05	0.000233	CcSEcCtD
Docetaxel—Rash—Cisplatin—urinary bladder cancer	2.26e-05	0.000233	CcSEcCtD
Docetaxel—Dermatitis—Cisplatin—urinary bladder cancer	2.25e-05	0.000232	CcSEcCtD
Docetaxel—Malnutrition—Epirubicin—urinary bladder cancer	2.25e-05	0.000232	CcSEcCtD
Docetaxel—Erythema—Epirubicin—urinary bladder cancer	2.25e-05	0.000232	CcSEcCtD
Docetaxel—Diarrhoea—Etoposide—urinary bladder cancer	2.24e-05	0.000231	CcSEcCtD
Docetaxel—Nausea—Fluorouracil—urinary bladder cancer	2.24e-05	0.000231	CcSEcCtD
Docetaxel—Eye disorder—Doxorubicin—urinary bladder cancer	2.24e-05	0.000231	CcSEcCtD
Docetaxel—Anaemia—Methotrexate—urinary bladder cancer	2.22e-05	0.000229	CcSEcCtD
Docetaxel—Cardiac disorder—Doxorubicin—urinary bladder cancer	2.22e-05	0.000229	CcSEcCtD
Docetaxel—Flushing—Doxorubicin—urinary bladder cancer	2.22e-05	0.000229	CcSEcCtD
Docetaxel—Dysgeusia—Epirubicin—urinary bladder cancer	2.2e-05	0.000227	CcSEcCtD
Docetaxel—Back pain—Epirubicin—urinary bladder cancer	2.18e-05	0.000225	CcSEcCtD
Docetaxel—Angiopathy—Doxorubicin—urinary bladder cancer	2.17e-05	0.000224	CcSEcCtD
Docetaxel—Dizziness—Etoposide—urinary bladder cancer	2.17e-05	0.000223	CcSEcCtD
Docetaxel—Muscle spasms—Epirubicin—urinary bladder cancer	2.16e-05	0.000223	CcSEcCtD
Docetaxel—Immune system disorder—Doxorubicin—urinary bladder cancer	2.16e-05	0.000223	CcSEcCtD
Docetaxel—Mediastinal disorder—Doxorubicin—urinary bladder cancer	2.16e-05	0.000222	CcSEcCtD
Docetaxel—Leukopenia—Methotrexate—urinary bladder cancer	2.15e-05	0.000222	CcSEcCtD
Docetaxel—Chills—Doxorubicin—urinary bladder cancer	2.15e-05	0.000221	CcSEcCtD
Docetaxel—Arrhythmia—Doxorubicin—urinary bladder cancer	2.14e-05	0.00022	CcSEcCtD
Docetaxel—Nausea—Cisplatin—urinary bladder cancer	2.13e-05	0.000219	CcSEcCtD
Docetaxel—Alopecia—Doxorubicin—urinary bladder cancer	2.11e-05	0.000218	CcSEcCtD
Docetaxel—Cough—Methotrexate—urinary bladder cancer	2.1e-05	0.000216	CcSEcCtD
Docetaxel—Mental disorder—Doxorubicin—urinary bladder cancer	2.1e-05	0.000216	CcSEcCtD
Docetaxel—Convulsion—Methotrexate—urinary bladder cancer	2.08e-05	0.000215	CcSEcCtD
Docetaxel—Vomiting—Etoposide—urinary bladder cancer	2.08e-05	0.000215	CcSEcCtD
Docetaxel—Erythema—Doxorubicin—urinary bladder cancer	2.08e-05	0.000215	CcSEcCtD
Docetaxel—Malnutrition—Doxorubicin—urinary bladder cancer	2.08e-05	0.000215	CcSEcCtD
Docetaxel—Anaemia—Epirubicin—urinary bladder cancer	2.08e-05	0.000215	CcSEcCtD
Docetaxel—Rash—Etoposide—urinary bladder cancer	2.07e-05	0.000213	CcSEcCtD
Docetaxel—Dermatitis—Etoposide—urinary bladder cancer	2.06e-05	0.000213	CcSEcCtD
Docetaxel—Headache—Etoposide—urinary bladder cancer	2.05e-05	0.000212	CcSEcCtD
Docetaxel—Arthralgia—Methotrexate—urinary bladder cancer	2.05e-05	0.000211	CcSEcCtD
Docetaxel—Chest pain—Methotrexate—urinary bladder cancer	2.05e-05	0.000211	CcSEcCtD
Docetaxel—Myalgia—Methotrexate—urinary bladder cancer	2.05e-05	0.000211	CcSEcCtD
Docetaxel—Dysgeusia—Doxorubicin—urinary bladder cancer	2.04e-05	0.00021	CcSEcCtD
Docetaxel—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	2.03e-05	0.00021	CcSEcCtD
Docetaxel—Syncope—Epirubicin—urinary bladder cancer	2.02e-05	0.000208	CcSEcCtD
Docetaxel—Leukopenia—Epirubicin—urinary bladder cancer	2.02e-05	0.000208	CcSEcCtD
Docetaxel—Back pain—Doxorubicin—urinary bladder cancer	2.01e-05	0.000208	CcSEcCtD
Docetaxel—Muscle spasms—Doxorubicin—urinary bladder cancer	2e-05	0.000206	CcSEcCtD
Docetaxel—Palpitations—Epirubicin—urinary bladder cancer	1.99e-05	0.000205	CcSEcCtD
Docetaxel—Confusional state—Methotrexate—urinary bladder cancer	1.98e-05	0.000204	CcSEcCtD
Docetaxel—Loss of consciousness—Epirubicin—urinary bladder cancer	1.98e-05	0.000204	CcSEcCtD
Docetaxel—Cough—Epirubicin—urinary bladder cancer	1.96e-05	0.000203	CcSEcCtD
Docetaxel—Anaphylactic shock—Methotrexate—urinary bladder cancer	1.96e-05	0.000202	CcSEcCtD
Docetaxel—Convulsion—Epirubicin—urinary bladder cancer	1.95e-05	0.000201	CcSEcCtD
Docetaxel—Infection—Methotrexate—urinary bladder cancer	1.95e-05	0.000201	CcSEcCtD
Docetaxel—Nausea—Etoposide—urinary bladder cancer	1.95e-05	0.000201	CcSEcCtD
Docetaxel—Hypertension—Epirubicin—urinary bladder cancer	1.94e-05	0.0002	CcSEcCtD
Docetaxel—Nervous system disorder—Methotrexate—urinary bladder cancer	1.93e-05	0.000199	CcSEcCtD
Docetaxel—Anaemia—Doxorubicin—urinary bladder cancer	1.93e-05	0.000199	CcSEcCtD
Docetaxel—Thrombocytopenia—Methotrexate—urinary bladder cancer	1.92e-05	0.000198	CcSEcCtD
Docetaxel—Myalgia—Epirubicin—urinary bladder cancer	1.92e-05	0.000198	CcSEcCtD
Docetaxel—Chest pain—Epirubicin—urinary bladder cancer	1.92e-05	0.000198	CcSEcCtD
Docetaxel—Arthralgia—Epirubicin—urinary bladder cancer	1.92e-05	0.000198	CcSEcCtD
Docetaxel—Skin disorder—Methotrexate—urinary bladder cancer	1.91e-05	0.000197	CcSEcCtD
Docetaxel—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	1.9e-05	0.000196	CcSEcCtD
Docetaxel—Dry mouth—Epirubicin—urinary bladder cancer	1.87e-05	0.000193	CcSEcCtD
Docetaxel—Anorexia—Methotrexate—urinary bladder cancer	1.87e-05	0.000193	CcSEcCtD
Docetaxel—Syncope—Doxorubicin—urinary bladder cancer	1.87e-05	0.000193	CcSEcCtD
Docetaxel—Leukopenia—Doxorubicin—urinary bladder cancer	1.86e-05	0.000192	CcSEcCtD
Docetaxel—Confusional state—Epirubicin—urinary bladder cancer	1.85e-05	0.000191	CcSEcCtD
Docetaxel—Palpitations—Doxorubicin—urinary bladder cancer	1.84e-05	0.00019	CcSEcCtD
Docetaxel—Anaphylactic shock—Epirubicin—urinary bladder cancer	1.84e-05	0.000189	CcSEcCtD
Docetaxel—Oedema—Epirubicin—urinary bladder cancer	1.84e-05	0.000189	CcSEcCtD
Docetaxel—Hypotension—Methotrexate—urinary bladder cancer	1.83e-05	0.000189	CcSEcCtD
Docetaxel—Loss of consciousness—Doxorubicin—urinary bladder cancer	1.83e-05	0.000189	CcSEcCtD
Docetaxel—Infection—Epirubicin—urinary bladder cancer	1.83e-05	0.000188	CcSEcCtD
Docetaxel—Cough—Doxorubicin—urinary bladder cancer	1.82e-05	0.000187	CcSEcCtD
Docetaxel—Shock—Epirubicin—urinary bladder cancer	1.81e-05	0.000186	CcSEcCtD
Docetaxel—Convulsion—Doxorubicin—urinary bladder cancer	1.8e-05	0.000186	CcSEcCtD
Docetaxel—Nervous system disorder—Epirubicin—urinary bladder cancer	1.8e-05	0.000186	CcSEcCtD
Docetaxel—Thrombocytopenia—Epirubicin—urinary bladder cancer	1.8e-05	0.000185	CcSEcCtD
Docetaxel—Hypertension—Doxorubicin—urinary bladder cancer	1.8e-05	0.000185	CcSEcCtD
Docetaxel—Tachycardia—Epirubicin—urinary bladder cancer	1.79e-05	0.000185	CcSEcCtD
Docetaxel—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	1.79e-05	0.000184	CcSEcCtD
Docetaxel—Skin disorder—Epirubicin—urinary bladder cancer	1.78e-05	0.000184	CcSEcCtD
Docetaxel—Insomnia—Methotrexate—urinary bladder cancer	1.78e-05	0.000183	CcSEcCtD
Docetaxel—Chest pain—Doxorubicin—urinary bladder cancer	1.77e-05	0.000183	CcSEcCtD
Docetaxel—Myalgia—Doxorubicin—urinary bladder cancer	1.77e-05	0.000183	CcSEcCtD
Docetaxel—Arthralgia—Doxorubicin—urinary bladder cancer	1.77e-05	0.000183	CcSEcCtD
Docetaxel—Paraesthesia—Methotrexate—urinary bladder cancer	1.76e-05	0.000182	CcSEcCtD
Docetaxel—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	1.76e-05	0.000182	CcSEcCtD
Docetaxel—Anorexia—Epirubicin—urinary bladder cancer	1.75e-05	0.000181	CcSEcCtD
Docetaxel—Dyspnoea—Methotrexate—urinary bladder cancer	1.75e-05	0.00018	CcSEcCtD
Docetaxel—Somnolence—Methotrexate—urinary bladder cancer	1.75e-05	0.00018	CcSEcCtD
Docetaxel—Dry mouth—Doxorubicin—urinary bladder cancer	1.73e-05	0.000179	CcSEcCtD
Docetaxel—Dyspepsia—Methotrexate—urinary bladder cancer	1.73e-05	0.000178	CcSEcCtD
Docetaxel—Hypotension—Epirubicin—urinary bladder cancer	1.72e-05	0.000177	CcSEcCtD
Docetaxel—Confusional state—Doxorubicin—urinary bladder cancer	1.71e-05	0.000177	CcSEcCtD
Docetaxel—Decreased appetite—Methotrexate—urinary bladder cancer	1.71e-05	0.000176	CcSEcCtD
Docetaxel—Anaphylactic shock—Doxorubicin—urinary bladder cancer	1.7e-05	0.000175	CcSEcCtD
Docetaxel—Oedema—Doxorubicin—urinary bladder cancer	1.7e-05	0.000175	CcSEcCtD
Docetaxel—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	1.69e-05	0.000175	CcSEcCtD
Docetaxel—Fatigue—Methotrexate—urinary bladder cancer	1.69e-05	0.000175	CcSEcCtD
Docetaxel—Infection—Doxorubicin—urinary bladder cancer	1.69e-05	0.000174	CcSEcCtD
Docetaxel—Pain—Methotrexate—urinary bladder cancer	1.68e-05	0.000173	CcSEcCtD
Docetaxel—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	1.67e-05	0.000173	CcSEcCtD
Docetaxel—Shock—Doxorubicin—urinary bladder cancer	1.67e-05	0.000172	CcSEcCtD
Docetaxel—Nervous system disorder—Doxorubicin—urinary bladder cancer	1.67e-05	0.000172	CcSEcCtD
Docetaxel—Thrombocytopenia—Doxorubicin—urinary bladder cancer	1.66e-05	0.000172	CcSEcCtD
Docetaxel—Insomnia—Epirubicin—urinary bladder cancer	1.66e-05	0.000171	CcSEcCtD
Docetaxel—Tachycardia—Doxorubicin—urinary bladder cancer	1.66e-05	0.000171	CcSEcCtD
Docetaxel—Skin disorder—Doxorubicin—urinary bladder cancer	1.65e-05	0.00017	CcSEcCtD
Docetaxel—Paraesthesia—Epirubicin—urinary bladder cancer	1.65e-05	0.00017	CcSEcCtD
Docetaxel—Dyspnoea—Epirubicin—urinary bladder cancer	1.64e-05	0.000169	CcSEcCtD
Docetaxel—Somnolence—Epirubicin—urinary bladder cancer	1.63e-05	0.000168	CcSEcCtD
Docetaxel—Anorexia—Doxorubicin—urinary bladder cancer	1.62e-05	0.000167	CcSEcCtD
Docetaxel—Feeling abnormal—Methotrexate—urinary bladder cancer	1.62e-05	0.000167	CcSEcCtD
Docetaxel—Dyspepsia—Epirubicin—urinary bladder cancer	1.62e-05	0.000167	CcSEcCtD
Docetaxel—Gastrointestinal pain—Methotrexate—urinary bladder cancer	1.61e-05	0.000166	CcSEcCtD
Docetaxel—Decreased appetite—Epirubicin—urinary bladder cancer	1.6e-05	0.000165	CcSEcCtD
Docetaxel—Hypotension—Doxorubicin—urinary bladder cancer	1.59e-05	0.000164	CcSEcCtD
Docetaxel—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	1.59e-05	0.000164	CcSEcCtD
Docetaxel—Fatigue—Epirubicin—urinary bladder cancer	1.58e-05	0.000163	CcSEcCtD
Docetaxel—Pain—Epirubicin—urinary bladder cancer	1.57e-05	0.000162	CcSEcCtD
Docetaxel—Constipation—Epirubicin—urinary bladder cancer	1.57e-05	0.000162	CcSEcCtD
Docetaxel—Body temperature increased—Methotrexate—urinary bladder cancer	1.55e-05	0.00016	CcSEcCtD
Docetaxel—Abdominal pain—Methotrexate—urinary bladder cancer	1.55e-05	0.00016	CcSEcCtD
Docetaxel—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	1.55e-05	0.00016	CcSEcCtD
Docetaxel—Insomnia—Doxorubicin—urinary bladder cancer	1.54e-05	0.000159	CcSEcCtD
Docetaxel—Paraesthesia—Doxorubicin—urinary bladder cancer	1.53e-05	0.000157	CcSEcCtD
Docetaxel—Dyspnoea—Doxorubicin—urinary bladder cancer	1.52e-05	0.000156	CcSEcCtD
Docetaxel—Feeling abnormal—Epirubicin—urinary bladder cancer	1.51e-05	0.000156	CcSEcCtD
Docetaxel—Somnolence—Doxorubicin—urinary bladder cancer	1.51e-05	0.000156	CcSEcCtD
Docetaxel—Gastrointestinal pain—Epirubicin—urinary bladder cancer	1.5e-05	0.000155	CcSEcCtD
Docetaxel—Dyspepsia—Doxorubicin—urinary bladder cancer	1.5e-05	0.000154	CcSEcCtD
Docetaxel—Decreased appetite—Doxorubicin—urinary bladder cancer	1.48e-05	0.000152	CcSEcCtD
Docetaxel—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	1.47e-05	0.000151	CcSEcCtD
Docetaxel—Fatigue—Doxorubicin—urinary bladder cancer	1.47e-05	0.000151	CcSEcCtD
Docetaxel—Constipation—Doxorubicin—urinary bladder cancer	1.45e-05	0.00015	CcSEcCtD
Docetaxel—Pain—Doxorubicin—urinary bladder cancer	1.45e-05	0.00015	CcSEcCtD
Docetaxel—Abdominal pain—Epirubicin—urinary bladder cancer	1.45e-05	0.00015	CcSEcCtD
Docetaxel—Body temperature increased—Epirubicin—urinary bladder cancer	1.45e-05	0.00015	CcSEcCtD
Docetaxel—Hypersensitivity—Methotrexate—urinary bladder cancer	1.45e-05	0.000149	CcSEcCtD
Docetaxel—Asthenia—Methotrexate—urinary bladder cancer	1.41e-05	0.000145	CcSEcCtD
Docetaxel—Feeling abnormal—Doxorubicin—urinary bladder cancer	1.4e-05	0.000144	CcSEcCtD
Docetaxel—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	1.39e-05	0.000143	CcSEcCtD
Docetaxel—Pruritus—Methotrexate—urinary bladder cancer	1.39e-05	0.000143	CcSEcCtD
Docetaxel—Hypersensitivity—Epirubicin—urinary bladder cancer	1.35e-05	0.00014	CcSEcCtD
Docetaxel—Abdominal pain—Doxorubicin—urinary bladder cancer	1.34e-05	0.000139	CcSEcCtD
Docetaxel—Body temperature increased—Doxorubicin—urinary bladder cancer	1.34e-05	0.000139	CcSEcCtD
Docetaxel—Diarrhoea—Methotrexate—urinary bladder cancer	1.34e-05	0.000139	CcSEcCtD
Docetaxel—Asthenia—Epirubicin—urinary bladder cancer	1.32e-05	0.000136	CcSEcCtD
Docetaxel—Pruritus—Epirubicin—urinary bladder cancer	1.3e-05	0.000134	CcSEcCtD
Docetaxel—Dizziness—Methotrexate—urinary bladder cancer	1.3e-05	0.000134	CcSEcCtD
Docetaxel—Diarrhoea—Epirubicin—urinary bladder cancer	1.26e-05	0.00013	CcSEcCtD
Docetaxel—Hypersensitivity—Doxorubicin—urinary bladder cancer	1.25e-05	0.000129	CcSEcCtD
Docetaxel—Vomiting—Methotrexate—urinary bladder cancer	1.25e-05	0.000129	CcSEcCtD
Docetaxel—Rash—Methotrexate—urinary bladder cancer	1.24e-05	0.000128	CcSEcCtD
Docetaxel—Dermatitis—Methotrexate—urinary bladder cancer	1.24e-05	0.000128	CcSEcCtD
Docetaxel—Headache—Methotrexate—urinary bladder cancer	1.23e-05	0.000127	CcSEcCtD
Docetaxel—Asthenia—Doxorubicin—urinary bladder cancer	1.22e-05	0.000126	CcSEcCtD
Docetaxel—Dizziness—Epirubicin—urinary bladder cancer	1.21e-05	0.000125	CcSEcCtD
Docetaxel—Pruritus—Doxorubicin—urinary bladder cancer	1.2e-05	0.000124	CcSEcCtD
Docetaxel—Vomiting—Epirubicin—urinary bladder cancer	1.17e-05	0.00012	CcSEcCtD
Docetaxel—Nausea—Methotrexate—urinary bladder cancer	1.17e-05	0.00012	CcSEcCtD
Docetaxel—Diarrhoea—Doxorubicin—urinary bladder cancer	1.16e-05	0.00012	CcSEcCtD
Docetaxel—Rash—Epirubicin—urinary bladder cancer	1.16e-05	0.000119	CcSEcCtD
Docetaxel—Dermatitis—Epirubicin—urinary bladder cancer	1.16e-05	0.000119	CcSEcCtD
Docetaxel—Headache—Epirubicin—urinary bladder cancer	1.15e-05	0.000119	CcSEcCtD
Docetaxel—Dizziness—Doxorubicin—urinary bladder cancer	1.12e-05	0.000116	CcSEcCtD
Docetaxel—Nausea—Epirubicin—urinary bladder cancer	1.09e-05	0.000113	CcSEcCtD
Docetaxel—Vomiting—Doxorubicin—urinary bladder cancer	1.08e-05	0.000111	CcSEcCtD
Docetaxel—Rash—Doxorubicin—urinary bladder cancer	1.07e-05	0.000111	CcSEcCtD
Docetaxel—Dermatitis—Doxorubicin—urinary bladder cancer	1.07e-05	0.00011	CcSEcCtD
Docetaxel—Headache—Doxorubicin—urinary bladder cancer	1.06e-05	0.00011	CcSEcCtD
Docetaxel—Nausea—Doxorubicin—urinary bladder cancer	1.01e-05	0.000104	CcSEcCtD
Docetaxel—TUBB4A—Cell Cycle—TP53—urinary bladder cancer	4.91e-06	8.8e-05	CbGpPWpGaD
Docetaxel—BCL2—Innate Immune System—KRAS—urinary bladder cancer	4.91e-06	8.79e-05	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—PRSS3—urinary bladder cancer	4.89e-06	8.77e-05	CbGpPWpGaD
Docetaxel—NR1I2—Gene Expression—MYC—urinary bladder cancer	4.89e-06	8.76e-05	CbGpPWpGaD
Docetaxel—SLCO1B3—Metabolism—ERCC2—urinary bladder cancer	4.88e-06	8.75e-05	CbGpPWpGaD
Docetaxel—ABCC1—Metabolism—NQO1—urinary bladder cancer	4.79e-06	8.58e-05	CbGpPWpGaD
Docetaxel—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	4.79e-06	8.57e-05	CbGpPWpGaD
Docetaxel—ABCG2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	4.75e-06	8.51e-05	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—NAT2—urinary bladder cancer	4.69e-06	8.4e-05	CbGpPWpGaD
Docetaxel—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	4.65e-06	8.33e-05	CbGpPWpGaD
Docetaxel—CYP1B1—Metabolism—NQO1—urinary bladder cancer	4.63e-06	8.3e-05	CbGpPWpGaD
Docetaxel—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	4.63e-06	8.29e-05	CbGpPWpGaD
Docetaxel—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	4.62e-06	8.27e-05	CbGpPWpGaD
Docetaxel—EGFR—Axon guidance—KRAS—urinary bladder cancer	4.6e-06	8.25e-05	CbGpPWpGaD
Docetaxel—SLCO1B3—Metabolism—MTHFR—urinary bladder cancer	4.59e-06	8.22e-05	CbGpPWpGaD
Docetaxel—CYP1B1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	4.5e-06	8.06e-05	CbGpPWpGaD
Docetaxel—TUBB4B—Cell Cycle—TP53—urinary bladder cancer	4.49e-06	8.04e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—RBX1—urinary bladder cancer	4.44e-06	7.96e-05	CbGpPWpGaD
Docetaxel—EGFR—Innate Immune System—ERBB2—urinary bladder cancer	4.43e-06	7.94e-05	CbGpPWpGaD
Docetaxel—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	4.41e-06	7.89e-05	CbGpPWpGaD
Docetaxel—ABCC1—Disease—NCOR1—urinary bladder cancer	4.39e-06	7.86e-05	CbGpPWpGaD
Docetaxel—BCL2—Immune System—ERBB2—urinary bladder cancer	4.37e-06	7.82e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling by NGF—HRAS—urinary bladder cancer	4.32e-06	7.75e-05	CbGpPWpGaD
Docetaxel—EGFR—Developmental Biology—MMP9—urinary bladder cancer	4.3e-06	7.71e-05	CbGpPWpGaD
Docetaxel—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	4.28e-06	7.67e-05	CbGpPWpGaD
Docetaxel—EGFR—Adaptive Immune System—ERBB2—urinary bladder cancer	4.26e-06	7.62e-05	CbGpPWpGaD
Docetaxel—ABCG2—Metabolism—NQO1—urinary bladder cancer	4.22e-06	7.55e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	4.2e-06	7.52e-05	CbGpPWpGaD
Docetaxel—CYP3A7—Metabolism—NQO1—urinary bladder cancer	4.18e-06	7.49e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—TSC1—urinary bladder cancer	4.18e-06	7.48e-05	CbGpPWpGaD
Docetaxel—BCL2—Innate Immune System—HRAS—urinary bladder cancer	4.17e-06	7.47e-05	CbGpPWpGaD
Docetaxel—EGFR—Disease—NCOR1—urinary bladder cancer	4.13e-06	7.4e-05	CbGpPWpGaD
Docetaxel—ABCC1—Disease—ERCC2—urinary bladder cancer	4.12e-06	7.39e-05	CbGpPWpGaD
Docetaxel—EGFR—Developmental Biology—EP300—urinary bladder cancer	4.08e-06	7.31e-05	CbGpPWpGaD
Docetaxel—ABCC1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	4.05e-06	7.26e-05	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—RRM2—urinary bladder cancer	4.05e-06	7.25e-05	CbGpPWpGaD
Docetaxel—ABCC1—Metabolism—GSTP1—urinary bladder cancer	4e-06	7.16e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	3.98e-06	7.13e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—NAT1—urinary bladder cancer	3.98e-06	7.13e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—JAG1—urinary bladder cancer	3.98e-06	7.12e-05	CbGpPWpGaD
Docetaxel—EGFR—Developmental Biology—SRC—urinary bladder cancer	3.97e-06	7.11e-05	CbGpPWpGaD
Docetaxel—BCL2—Immune System—IL2—urinary bladder cancer	3.96e-06	7.09e-05	CbGpPWpGaD
Docetaxel—CYP1B1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3.92e-06	7.03e-05	CbGpPWpGaD
Docetaxel—EGFR—Axon guidance—HRAS—urinary bladder cancer	3.91e-06	7.01e-05	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—TYMP—urinary bladder cancer	3.91e-06	7.01e-05	CbGpPWpGaD
Docetaxel—EGFR—Disease—ERCC2—urinary bladder cancer	3.89e-06	6.96e-05	CbGpPWpGaD
Docetaxel—ABCC1—Disease—MTHFR—urinary bladder cancer	3.88e-06	6.94e-05	CbGpPWpGaD
Docetaxel—ABCC1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.87e-06	6.93e-05	CbGpPWpGaD
Docetaxel—CYP1B1—Metabolism—GSTP1—urinary bladder cancer	3.87e-06	6.92e-05	CbGpPWpGaD
Docetaxel—ABCC1—Disease—TERT—urinary bladder cancer	3.86e-06	6.92e-05	CbGpPWpGaD
Docetaxel—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	3.84e-06	6.88e-05	CbGpPWpGaD
Docetaxel—EGFR—Innate Immune System—CDKN1A—urinary bladder cancer	3.79e-06	6.79e-05	CbGpPWpGaD
Docetaxel—EGFR—Innate Immune System—PTEN—urinary bladder cancer	3.78e-06	6.77e-05	CbGpPWpGaD
Docetaxel—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	3.75e-06	6.73e-05	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—HPGDS—urinary bladder cancer	3.75e-06	6.71e-05	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—ENO2—urinary bladder cancer	3.75e-06	6.71e-05	CbGpPWpGaD
Docetaxel—CYP1B1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.74e-06	6.7e-05	CbGpPWpGaD
Docetaxel—BCL2—Immune System—CDKN1A—urinary bladder cancer	3.73e-06	6.68e-05	CbGpPWpGaD
Docetaxel—BCL2—Immune System—PTEN—urinary bladder cancer	3.72e-06	6.67e-05	CbGpPWpGaD
Docetaxel—SLCO1B3—Metabolism—PPARG—urinary bladder cancer	3.72e-06	6.67e-05	CbGpPWpGaD
Docetaxel—ABCC1—Metabolism—TYMS—urinary bladder cancer	3.72e-06	6.66e-05	CbGpPWpGaD
Docetaxel—ABCC1—Metabolism—GSTM1—urinary bladder cancer	3.67e-06	6.58e-05	CbGpPWpGaD
Docetaxel—ABCC1—Metabolism—NCOR1—urinary bladder cancer	3.67e-06	6.58e-05	CbGpPWpGaD
Docetaxel—EGFR—Disease—MTHFR—urinary bladder cancer	3.65e-06	6.54e-05	CbGpPWpGaD
Docetaxel—EGFR—Disease—TERT—urinary bladder cancer	3.64e-06	6.53e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	3.64e-06	6.52e-05	CbGpPWpGaD
Docetaxel—EGFR—Adaptive Immune System—CDKN1A—urinary bladder cancer	3.64e-06	6.52e-05	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—GSTT1—urinary bladder cancer	3.64e-06	6.51e-05	CbGpPWpGaD
Docetaxel—EGFR—Adaptive Immune System—PTEN—urinary bladder cancer	3.63e-06	6.5e-05	CbGpPWpGaD
Docetaxel—EGFR—Immune System—FGFR3—urinary bladder cancer	3.62e-06	6.49e-05	CbGpPWpGaD
Docetaxel—EGFR—Innate Immune System—EP300—urinary bladder cancer	3.6e-06	6.46e-05	CbGpPWpGaD
Docetaxel—CYP1B1—Metabolism—TYMS—urinary bladder cancer	3.59e-06	6.44e-05	CbGpPWpGaD
Docetaxel—SLCO1B3—Metabolism—CREBBP—urinary bladder cancer	3.58e-06	6.41e-05	CbGpPWpGaD
Docetaxel—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	3.58e-06	6.41e-05	CbGpPWpGaD
Docetaxel—CYP1B1—Metabolism—NCOR1—urinary bladder cancer	3.55e-06	6.36e-05	CbGpPWpGaD
Docetaxel—CYP1B1—Metabolism—GSTM1—urinary bladder cancer	3.55e-06	6.36e-05	CbGpPWpGaD
Docetaxel—BCL2—Immune System—EP300—urinary bladder cancer	3.55e-06	6.36e-05	CbGpPWpGaD
Docetaxel—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	3.55e-06	6.35e-05	CbGpPWpGaD
Docetaxel—ABCC1—Disease—FGFR3—urinary bladder cancer	3.55e-06	6.35e-05	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—NAT2—urinary bladder cancer	3.54e-06	6.34e-05	CbGpPWpGaD
Docetaxel—ABCC1—Metabolism—GPX1—urinary bladder cancer	3.52e-06	6.3e-05	CbGpPWpGaD
Docetaxel—ABCG2—Metabolism—GSTP1—urinary bladder cancer	3.52e-06	6.3e-05	CbGpPWpGaD
Docetaxel—EGFR—Innate Immune System—SRC—urinary bladder cancer	3.5e-06	6.28e-05	CbGpPWpGaD
Docetaxel—CYP3A7—Metabolism—GSTP1—urinary bladder cancer	3.49e-06	6.24e-05	CbGpPWpGaD
Docetaxel—ABCC1—Metabolism—ERCC2—urinary bladder cancer	3.45e-06	6.19e-05	CbGpPWpGaD
Docetaxel—BCL2—Immune System—SRC—urinary bladder cancer	3.45e-06	6.19e-05	CbGpPWpGaD
Docetaxel—CYP1B1—Metabolism—GPX1—urinary bladder cancer	3.4e-06	6.09e-05	CbGpPWpGaD
Docetaxel—EGFR—Adaptive Immune System—SRC—urinary bladder cancer	3.37e-06	6.03e-05	CbGpPWpGaD
Docetaxel—EGFR—Disease—FGFR3—urinary bladder cancer	3.34e-06	5.99e-05	CbGpPWpGaD
Docetaxel—CYP1B1—Metabolism—ERCC2—urinary bladder cancer	3.34e-06	5.98e-05	CbGpPWpGaD
Docetaxel—EGFR—Developmental Biology—TNF—urinary bladder cancer	3.31e-06	5.93e-05	CbGpPWpGaD
Docetaxel—EGFR—Developmental Biology—KRAS—urinary bladder cancer	3.29e-06	5.89e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	3.28e-06	5.87e-05	CbGpPWpGaD
Docetaxel—ABCG2—Metabolism—TYMS—urinary bladder cancer	3.27e-06	5.86e-05	CbGpPWpGaD
Docetaxel—ABCC1—Metabolism—MTHFR—urinary bladder cancer	3.25e-06	5.81e-05	CbGpPWpGaD
Docetaxel—CYP3A7—Metabolism—TYMS—urinary bladder cancer	3.24e-06	5.81e-05	CbGpPWpGaD
Docetaxel—ABCG2—Metabolism—NCOR1—urinary bladder cancer	3.23e-06	5.79e-05	CbGpPWpGaD
Docetaxel—ABCG2—Metabolism—GSTM1—urinary bladder cancer	3.23e-06	5.79e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—S100B—urinary bladder cancer	3.22e-06	5.77e-05	CbGpPWpGaD
Docetaxel—CYP3A7—Metabolism—GSTM1—urinary bladder cancer	3.2e-06	5.74e-05	CbGpPWpGaD
Docetaxel—CYP3A7—Metabolism—NCOR1—urinary bladder cancer	3.2e-06	5.74e-05	CbGpPWpGaD
Docetaxel—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	3.15e-06	5.65e-05	CbGpPWpGaD
Docetaxel—CYP1B1—Metabolism—MTHFR—urinary bladder cancer	3.14e-06	5.62e-05	CbGpPWpGaD
Docetaxel—ABCG2—Metabolism—GPX1—urinary bladder cancer	3.09e-06	5.54e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	3.09e-06	5.54e-05	CbGpPWpGaD
Docetaxel—EGFR—Immune System—CREBBP—urinary bladder cancer	3.08e-06	5.52e-05	CbGpPWpGaD
Docetaxel—CYP3A7—Metabolism—GPX1—urinary bladder cancer	3.07e-06	5.5e-05	CbGpPWpGaD
Docetaxel—EGFR—Immune System—CDH1—urinary bladder cancer	3.06e-06	5.48e-05	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—RRM2—urinary bladder cancer	3.05e-06	5.47e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling by GPCR—RHOA—urinary bladder cancer	3.05e-06	5.47e-05	CbGpPWpGaD
Docetaxel—ABCG2—Metabolism—ERCC2—urinary bladder cancer	3.04e-06	5.44e-05	CbGpPWpGaD
Docetaxel—BCL2—Immune System—EGFR—urinary bladder cancer	3.03e-06	5.42e-05	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—NQO1—urinary bladder cancer	3.02e-06	5.41e-05	CbGpPWpGaD
Docetaxel—ABCC1—Disease—CREBBP—urinary bladder cancer	3.02e-06	5.41e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	3.01e-06	5.4e-05	CbGpPWpGaD
Docetaxel—CYP3A7—Metabolism—ERCC2—urinary bladder cancer	3.01e-06	5.4e-05	CbGpPWpGaD
Docetaxel—SLCO1B3—Metabolism—PTGS2—urinary bladder cancer	2.93e-06	5.25e-05	CbGpPWpGaD
Docetaxel—EGFR—Innate Immune System—KRAS—urinary bladder cancer	2.9e-06	5.2e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—NCOR1—urinary bladder cancer	2.89e-06	5.19e-05	CbGpPWpGaD
Docetaxel—BCL2—Immune System—KRAS—urinary bladder cancer	2.86e-06	5.12e-05	CbGpPWpGaD
Docetaxel—ABCG2—Metabolism—MTHFR—urinary bladder cancer	2.86e-06	5.12e-05	CbGpPWpGaD
Docetaxel—EGFR—Disease—CREBBP—urinary bladder cancer	2.85e-06	5.1e-05	CbGpPWpGaD
Docetaxel—CYP3A7—Metabolism—MTHFR—urinary bladder cancer	2.83e-06	5.07e-05	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—HPGDS—urinary bladder cancer	2.83e-06	5.07e-05	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—ENO2—urinary bladder cancer	2.83e-06	5.07e-05	CbGpPWpGaD
Docetaxel—EGFR—Developmental Biology—HRAS—urinary bladder cancer	2.79e-06	5e-05	CbGpPWpGaD
Docetaxel—EGFR—Adaptive Immune System—KRAS—urinary bladder cancer	2.79e-06	4.99e-05	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—GSTT1—urinary bladder cancer	2.74e-06	4.91e-05	CbGpPWpGaD
Docetaxel—ABCC1—Disease—RHOA—urinary bladder cancer	2.73e-06	4.89e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling by GPCR—CXCL8—urinary bladder cancer	2.68e-06	4.8e-05	CbGpPWpGaD
Docetaxel—ABCC1—Metabolism—PPARG—urinary bladder cancer	2.63e-06	4.72e-05	CbGpPWpGaD
Docetaxel—EGFR—Immune System—ERBB2—urinary bladder cancer	2.58e-06	4.62e-05	CbGpPWpGaD
Docetaxel—EGFR—Disease—RHOA—urinary bladder cancer	2.57e-06	4.61e-05	CbGpPWpGaD
Docetaxel—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	2.57e-06	4.6e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling by GPCR—IL2—urinary bladder cancer	2.56e-06	4.59e-05	CbGpPWpGaD
Docetaxel—SLCO1B3—Metabolism—PTEN—urinary bladder cancer	2.55e-06	4.58e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—TERT—urinary bladder cancer	2.55e-06	4.57e-05	CbGpPWpGaD
Docetaxel—CYP1B1—Metabolism—PPARG—urinary bladder cancer	2.55e-06	4.56e-05	CbGpPWpGaD
Docetaxel—ABCC1—Metabolism—CREBBP—urinary bladder cancer	2.53e-06	4.53e-05	CbGpPWpGaD
Docetaxel—ABCC1—Disease—ERBB2—urinary bladder cancer	2.53e-06	4.53e-05	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—GSTP1—urinary bladder cancer	2.52e-06	4.51e-05	CbGpPWpGaD
Docetaxel—ABCC1—Disease—PTGS2—urinary bladder cancer	2.47e-06	4.43e-05	CbGpPWpGaD
Docetaxel—EGFR—Innate Immune System—HRAS—urinary bladder cancer	2.47e-06	4.42e-05	CbGpPWpGaD
Docetaxel—CYP1B1—Metabolism—CREBBP—urinary bladder cancer	2.45e-06	4.38e-05	CbGpPWpGaD
Docetaxel—SLCO1B3—Metabolism—EP300—urinary bladder cancer	2.44e-06	4.36e-05	CbGpPWpGaD
Docetaxel—BCL2—Immune System—HRAS—urinary bladder cancer	2.43e-06	4.35e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—TYMP—urinary bladder cancer	2.41e-06	4.32e-05	CbGpPWpGaD
Docetaxel—EGFR—Disease—ERBB2—urinary bladder cancer	2.38e-06	4.27e-05	CbGpPWpGaD
Docetaxel—EGFR—Adaptive Immune System—HRAS—urinary bladder cancer	2.37e-06	4.24e-05	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—TYMS—urinary bladder cancer	2.34e-06	4.2e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—FGFR3—urinary bladder cancer	2.34e-06	4.19e-05	CbGpPWpGaD
Docetaxel—EGFR—Immune System—IL2—urinary bladder cancer	2.34e-06	4.19e-05	CbGpPWpGaD
Docetaxel—EGFR—Disease—PTGS2—urinary bladder cancer	2.33e-06	4.17e-05	CbGpPWpGaD
Docetaxel—ABCG2—Metabolism—PPARG—urinary bladder cancer	2.32e-06	4.15e-05	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—GSTM1—urinary bladder cancer	2.32e-06	4.15e-05	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—NCOR1—urinary bladder cancer	2.32e-06	4.15e-05	CbGpPWpGaD
Docetaxel—CYP3A7—Metabolism—PPARG—urinary bladder cancer	2.3e-06	4.11e-05	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—NQO1—urinary bladder cancer	2.28e-06	4.08e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—ESR1—urinary bladder cancer	2.27e-06	4.07e-05	CbGpPWpGaD
Docetaxel—ABCG2—Metabolism—CREBBP—urinary bladder cancer	2.22e-06	3.99e-05	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—GPX1—urinary bladder cancer	2.22e-06	3.97e-05	CbGpPWpGaD
Docetaxel—EGFR—Immune System—CDKN1A—urinary bladder cancer	2.21e-06	3.95e-05	CbGpPWpGaD
Docetaxel—CYP3A7—Metabolism—CREBBP—urinary bladder cancer	2.21e-06	3.95e-05	CbGpPWpGaD
Docetaxel—EGFR—Immune System—PTEN—urinary bladder cancer	2.2e-06	3.94e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—NAT2—urinary bladder cancer	2.18e-06	3.9e-05	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—ERCC2—urinary bladder cancer	2.18e-06	3.9e-05	CbGpPWpGaD
Docetaxel—ABCC1—Disease—CDKN1A—urinary bladder cancer	2.16e-06	3.87e-05	CbGpPWpGaD
Docetaxel—ABCC1—Disease—PTEN—urinary bladder cancer	2.16e-06	3.86e-05	CbGpPWpGaD
Docetaxel—EGFR—Immune System—EP300—urinary bladder cancer	2.1e-06	3.76e-05	CbGpPWpGaD
Docetaxel—ABCC1—Metabolism—PTGS2—urinary bladder cancer	2.07e-06	3.71e-05	CbGpPWpGaD
Docetaxel—ABCC1—Disease—EP300—urinary bladder cancer	2.06e-06	3.68e-05	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—MTHFR—urinary bladder cancer	2.05e-06	3.67e-05	CbGpPWpGaD
Docetaxel—EGFR—Immune System—SRC—urinary bladder cancer	2.04e-06	3.66e-05	CbGpPWpGaD
Docetaxel—EGFR—Disease—CDKN1A—urinary bladder cancer	2.04e-06	3.65e-05	CbGpPWpGaD
Docetaxel—EGFR—Disease—PTEN—urinary bladder cancer	2.03e-06	3.64e-05	CbGpPWpGaD
Docetaxel—CYP1B1—Metabolism—PTGS2—urinary bladder cancer	2e-06	3.59e-05	CbGpPWpGaD
Docetaxel—ABCC1—Disease—SRC—urinary bladder cancer	2e-06	3.58e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—CREBBP—urinary bladder cancer	1.99e-06	3.57e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—IGF1—urinary bladder cancer	1.97e-06	3.53e-05	CbGpPWpGaD
Docetaxel—EGFR—Disease—EP300—urinary bladder cancer	1.94e-06	3.47e-05	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—GSTP1—urinary bladder cancer	1.9e-06	3.41e-05	CbGpPWpGaD
Docetaxel—EGFR—Disease—SRC—urinary bladder cancer	1.88e-06	3.38e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—RRM2—urinary bladder cancer	1.88e-06	3.37e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling by GPCR—KRAS—urinary bladder cancer	1.85e-06	3.31e-05	CbGpPWpGaD
Docetaxel—ABCG2—Metabolism—PTGS2—urinary bladder cancer	1.82e-06	3.26e-05	CbGpPWpGaD
Docetaxel—CYP3A7—Metabolism—PTGS2—urinary bladder cancer	1.81e-06	3.24e-05	CbGpPWpGaD
Docetaxel—ABCC1—Metabolism—PTEN—urinary bladder cancer	1.81e-06	3.23e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—RHOA—urinary bladder cancer	1.8e-06	3.23e-05	CbGpPWpGaD
Docetaxel—ABCC1—Disease—MYC—urinary bladder cancer	1.79e-06	3.21e-05	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—TYMS—urinary bladder cancer	1.77e-06	3.17e-05	CbGpPWpGaD
Docetaxel—ABCC1—Disease—EGFR—urinary bladder cancer	1.75e-06	3.14e-05	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—NCOR1—urinary bladder cancer	1.75e-06	3.13e-05	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—GSTM1—urinary bladder cancer	1.75e-06	3.13e-05	CbGpPWpGaD
Docetaxel—CYP1B1—Metabolism—PTEN—urinary bladder cancer	1.75e-06	3.13e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	1.74e-06	3.12e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—ENO2—urinary bladder cancer	1.74e-06	3.12e-05	CbGpPWpGaD
Docetaxel—ABCC1—Metabolism—EP300—urinary bladder cancer	1.72e-06	3.08e-05	CbGpPWpGaD
Docetaxel—EGFR—Immune System—KRAS—urinary bladder cancer	1.69e-06	3.03e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	1.69e-06	3.03e-05	CbGpPWpGaD
Docetaxel—EGFR—Disease—MYC—urinary bladder cancer	1.69e-06	3.03e-05	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—GPX1—urinary bladder cancer	1.67e-06	3e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—ERBB2—urinary bladder cancer	1.67e-06	2.99e-05	CbGpPWpGaD
Docetaxel—CYP1B1—Metabolism—EP300—urinary bladder cancer	1.67e-06	2.98e-05	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—PPARG—urinary bladder cancer	1.66e-06	2.97e-05	CbGpPWpGaD
Docetaxel—ABCC1—Disease—KRAS—urinary bladder cancer	1.66e-06	2.97e-05	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—ERCC2—urinary bladder cancer	1.64e-06	2.94e-05	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—CREBBP—urinary bladder cancer	1.59e-06	2.86e-05	CbGpPWpGaD
Docetaxel—ABCG2—Metabolism—PTEN—urinary bladder cancer	1.59e-06	2.85e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—CXCL8—urinary bladder cancer	1.58e-06	2.84e-05	CbGpPWpGaD
Docetaxel—CYP3A7—Metabolism—PTEN—urinary bladder cancer	1.57e-06	2.82e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling by GPCR—HRAS—urinary bladder cancer	1.57e-06	2.82e-05	CbGpPWpGaD
Docetaxel—EGFR—Disease—KRAS—urinary bladder cancer	1.56e-06	2.8e-05	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—MTHFR—urinary bladder cancer	1.54e-06	2.77e-05	CbGpPWpGaD
Docetaxel—ABCG2—Metabolism—EP300—urinary bladder cancer	1.52e-06	2.71e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—IL2—urinary bladder cancer	1.51e-06	2.71e-05	CbGpPWpGaD
Docetaxel—CYP3A7—Metabolism—EP300—urinary bladder cancer	1.5e-06	2.69e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—CCND1—urinary bladder cancer	1.47e-06	2.64e-05	CbGpPWpGaD
Docetaxel—EGFR—Immune System—HRAS—urinary bladder cancer	1.44e-06	2.57e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—MMP9—urinary bladder cancer	1.43e-06	2.56e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—CDKN1A—urinary bladder cancer	1.43e-06	2.56e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—PTEN—urinary bladder cancer	1.42e-06	2.55e-05	CbGpPWpGaD
Docetaxel—ABCC1—Disease—HRAS—urinary bladder cancer	1.41e-06	2.52e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—NQO1—urinary bladder cancer	1.4e-06	2.52e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—EP300—urinary bladder cancer	1.36e-06	2.43e-05	CbGpPWpGaD
Docetaxel—EGFR—Disease—HRAS—urinary bladder cancer	1.33e-06	2.38e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—SRC—urinary bladder cancer	1.32e-06	2.36e-05	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—PTGS2—urinary bladder cancer	1.31e-06	2.34e-05	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—PPARG—urinary bladder cancer	1.25e-06	2.24e-05	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—CREBBP—urinary bladder cancer	1.2e-06	2.15e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—MYC—urinary bladder cancer	1.18e-06	2.12e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	1.17e-06	2.1e-05	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—PTEN—urinary bladder cancer	1.14e-06	2.04e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—KRAS—urinary bladder cancer	1.09e-06	1.96e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—TYMS—urinary bladder cancer	1.09e-06	1.95e-05	CbGpPWpGaD
Docetaxel—CYP3A5—Metabolism—EP300—urinary bladder cancer	1.09e-06	1.94e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	1.08e-06	1.93e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	1.08e-06	1.93e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—GPX1—urinary bladder cancer	1.03e-06	1.85e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	1.01e-06	1.81e-05	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—PTGS2—urinary bladder cancer	9.85e-07	1.76e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—TP53—urinary bladder cancer	9.71e-07	1.74e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	9.51e-07	1.7e-05	CbGpPWpGaD
Docetaxel—EGFR—Signaling Pathways—HRAS—urinary bladder cancer	9.29e-07	1.66e-05	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—PTEN—urinary bladder cancer	8.59e-07	1.54e-05	CbGpPWpGaD
Docetaxel—ABCB1—Metabolism—EP300—urinary bladder cancer	8.19e-07	1.47e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—PPARG—urinary bladder cancer	7.71e-07	1.38e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	7.41e-07	1.33e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	6.07e-07	1.09e-05	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—PTEN—urinary bladder cancer	5.29e-07	9.48e-06	CbGpPWpGaD
Docetaxel—CYP3A4—Metabolism—EP300—urinary bladder cancer	5.05e-07	9.04e-06	CbGpPWpGaD
